The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.
Cancer
Health sciences
Immunology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
17
03
2022
revised:
14
04
2022
accepted:
01
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
The most frequent genetic aberration leading to infant ALL (iALL) is the chromosomal translocation t(4;11), generating the fusion oncogenes
Identifiants
pubmed: 35800767
doi: 10.1016/j.isci.2022.104613
pii: S2589-0042(22)00885-9
pmc: PMC9253708
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104613Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Nat Immunol. 2004 Mar;5(3):266-71
pubmed: 14758358
Cancer Cell. 2014 Jun 16;25(6):778-93
pubmed: 24937459
Am J Pathol. 2005 Aug;167(2):465-73
pubmed: 16049332
Lupus Sci Med. 2016 Apr 08;3(1):e000146
pubmed: 27099766
Cell. 2020 Aug 20;182(4):992-1008.e21
pubmed: 32710817
Haematologica. 2019 Jun;104(6):1176-1188
pubmed: 30679323
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D91-4
pubmed: 14681366
Immunity. 1999 Oct;11(4):423-32
pubmed: 10549624
Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
J Immunol. 2008 Apr 15;180(8):5737-45
pubmed: 18390759
Cancer Cell. 2008 Jul 8;14(1):47-58
pubmed: 18598943
Blood. 2015 Sep 10;126(11):1302-13
pubmed: 26186938
Nature. 2016 Feb 11;530(7589):223-7
pubmed: 26863982
Lancet. 1999 Oct 30;354(9189):1499-503
pubmed: 10551495
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Syst Biol. 2017 Oct 3;11(Suppl 5):91
pubmed: 28984203
Blood. 2019 Oct 24;134(17):1415-1429
pubmed: 31501154
Nat Med. 2019 May;25(5):767-775
pubmed: 31011208
Neuro Oncol. 2020 Mar 5;22(3):333-344
pubmed: 31634400
Cancer Res. 2010 Dec 1;70(23):9581-90
pubmed: 21098714
J Clin Oncol. 2010 May 10;28(14):2339-47
pubmed: 20385996
Am J Pathol. 2013 Jun;182(6):2204-13
pubmed: 23578385
J Allergy Clin Immunol. 2010 Aug;126(2):280-9, 289.e1-7
pubmed: 20624644
Eur J Haematol. 2009 Nov;83(5):406-19
pubmed: 19558506
Lancet Oncol. 2020 Apr;21(4):541-550
pubmed: 32192573
J Exp Clin Cancer Res. 2018 Aug 29;37(1):204
pubmed: 30157922
Eur J Immunol. 2008 Feb;38(2):528-36
pubmed: 18203138
Nat Commun. 2021 Nov 25;12(1):6905
pubmed: 34824279
Blood. 2003 Oct 1;102(7):2321-33
pubmed: 12791663
J Clin Oncol. 2019 Sep 1;37(25):2246-2256
pubmed: 31283407
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Front Immunol. 2020 Aug 28;11:2104
pubmed: 32983168
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Sci Rep. 2017 Mar 14;7:44486
pubmed: 28290526
Immunity. 2008 Jun;28(6):870-80
pubmed: 18513999
Leukemia. 2016 May;30(5):1184-7
pubmed: 26369984
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):222-227
pubmed: 33095146
Blood. 2017 Mar 23;129(12):1617-1626
pubmed: 28159735
Cancer Res. 2012 Dec 1;72(23):6130-41
pubmed: 23026134
J Immunol. 2015 Feb 15;194(4):1534-44
pubmed: 25560409
Nat Genet. 2015 Apr;47(4):330-7
pubmed: 25730765
Haematologica. 2019 Jun;104(6):1136-1142
pubmed: 30545927
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4
pubmed: 9391133
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Cancer Res. 2005 Feb 15;65(4):1442-9
pubmed: 15735032
J Exp Med. 2003 Jan 20;197(2):181-93
pubmed: 12538658
J Immunol. 2014 Feb 15;192(4):1502-11
pubmed: 24453244
Nature. 1999 Jan 21;397(6716):263-6
pubmed: 9930702
J Exp Med. 2014 Sep 22;211(10):1925-35
pubmed: 25180064
Biotechnol J. 2015 Apr;10(4):647-53
pubmed: 25650551
Nat Med. 2003 Sep;9(9):1151-7
pubmed: 12910264
Int J Cancer. 2001 Apr 1;92(1):96-105
pubmed: 11279612
Cell Stem Cell. 2018 Mar 1;22(3):445-453.e5
pubmed: 29456159
Exp Hematol. 2004 Jul;32(7):622-9
pubmed: 15246158
Leukemia. 2018 Feb;32(2):273-284
pubmed: 28701730
Oncoimmunology. 2016 Mar 10;5(5):e1141857
pubmed: 27467961
Blood. 2010 Apr 8;115(14):2835-44
pubmed: 20032505
Nat Immunol. 2005 May;6(5):472-80
pubmed: 15834410
Lancet. 2007 Jul 21;370(9583):240-250
pubmed: 17658395
Sci Transl Med. 2019 Jun 26;11(498):
pubmed: 31243155
Lancet Oncol. 2020 Jan;21(1):121-133
pubmed: 31812554
Blood. 2012 Feb 23;119(8):1872-81
pubmed: 22210879
Front Immunol. 2018 Sep 26;9:2227
pubmed: 30319662
Adv Exp Med Biol. 1994;355:15-20
pubmed: 7709815
Nature. 2011 Jun 08;474(7350):216-9
pubmed: 21654805
Nat Rev Cancer. 2003 Sep;3(9):639-49
pubmed: 12951583
PLoS One. 2014 Jan 24;9(1):e87265
pubmed: 24475259
Eur J Immunol. 2006 Jun;36(6):1374-85
pubmed: 16708405
Immunity. 2012 Oct 19;37(4):685-96
pubmed: 23021953
Blood. 2015 Feb 5;125(6):967-80
pubmed: 25538041
Nat Immunol. 2001 Mar;2(3):203-9
pubmed: 11224518
Exp Hematol. 2021 Jan;93:38-43.e5
pubmed: 33069783
Blood. 2012 May 10;119(19):4430-40
pubmed: 22438251
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6198-203
pubmed: 11983910
Oncotarget. 2016 Jun 7;7(23):35341-52
pubmed: 27175594
Arthritis Rheumatol. 2018 Jul;70(7):1071-1076
pubmed: 29513931
Nat Med. 2002 Sep;8(9):1024-32
pubmed: 12145647
Cell Stem Cell. 2008 Apr 10;2(4):380-91
pubmed: 18397757
J Immunol. 2012 Feb 15;188(4):1698-707
pubmed: 22231701
Cell Rep. 2019 May 28;27(9):2537-2547.e5
pubmed: 31141680
Cancer Res. 2004 Nov 15;64(22):8451-5
pubmed: 15548717
Blood. 2019 Jan 17;133(3):205-214
pubmed: 30459160